journal article·2026-07Open access

Paternal Caffeine Exposure Programs Offspring Stress Vulnerability via Sperm Dlk1‐Dio3 Imprinting‐Directed Remodeling of a Novel Neural Circuit

Mengxi Lu, Gaole Dai, Sen Zhu, Shuai Zhang, Tingting Wang, Yuan Meng, Fang Yang, Xiaoyi Han, Hui Wang, Hao Kou, Dan Xu

Advanced Science· Volume 13· Issue 40

Abstract

ABSTRACT Paternal environmental exposures program offspring neurodevelopment via sperm epigenetics, yet mechanisms for intergenerational hypothalamic–pituitary–adrenal (HPA) axis dysregulation, a core hub for stress disorders, remain elusive. Using a paternal preconception caffeine exposure (PPCE) rat model with in vitro fertilization to exclude maternal confounders, we uncover a novel pathway linking sperm epigenetics to offspring HPA axis hyperresponsivity. By elevating paternal corticosterone, PPCE induces hypomethylation at the intergenic differentially methylated region (IG‐DMR) within sperm Dlk1‐Dio3 domain. This epigenetic alteration evades postfertilization reprogramming, persists in offspring hippocampus, and derepresses the maternally expressed miRNA cluster, causing posttranscriptional downregulation of glutaminase (GLS). Hippocampal GLS deficiency impairs glutamatergic neurotransmission in a novel circuit: ventral hippocampal CA1 glutamatergic neurons (vCA1 Glu ) → piriform cortex γ‐aminobutyric acid‐ergic neurons (Pir GABA ) → paraventricular nucleus corticotropin‐releasing hormone neurons (PVN CRH ). Chemogenetic activation of this circuit rescues HPA axis hyperresponsivity and affective phenotypes. Clinically, sperm IG‐DMR hypomethylation correlates with elevated plasma cortisol in prospective fathers. Importantly, paternal folic acid supplementation prevents these epigenetic alterations and restores offspring stress homeostasis. Our study delineates an intergenerational mechanism and identifies a potentially translatable prenatal intervention strategy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Genetic Syndromes and Imprinting · Prenatal Substance Exposure Effects · Neuroendocrine regulation and behavior

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Obstetrics School of Pharmaceutical Sciences Zhongnan Hospital of Wuhan University Wuhan University Wuhan China

Department of Pharmacology Taikang Medical School (School of Basic Medical Sciences) Wuhan University Wuhan China

Hubei Provincial Key Laboratory of Developmentally Originated Disease Wuhan China

Department of Pharmacy Zhongnan Hospital of Wuhan University Wuhan China

Key Laboratory of Combinatorial Biosynthesis and Drug Discovery Ministry of Education China

Funding

National Natural Science Foundation of China · National Key Research and Development Program of China

References (74)

Show source-provided references
1. 10.1016/j.yfrne.2019.10081910.1016/j.yfrne.2019.100819 ↗
2. 10.1152/physrev.00021.202310.1152/physrev.00021.2023 ↗
3. 10.1007/s10571‐011‐9784‐010.1007/s10571‐011‐9784‐0 ↗
4. 10.1152/physrev.00041.200610.1152/physrev.00041.2006 ↗
5. 10.3390/ijms2607294010.3390/ijms26072940 ↗
6. 10.1002/dmrr.284210.1002/dmrr.2842 ↗
7. 10.1016/bs.acc.2024.06.00810.1016/bs.acc.2024.06.008 ↗
8. 10.1523/JNEUROSCI.16‐12‐03943.199610.1523/JNEUROSCI.16‐12‐03943.1996 ↗
9. 10.1016/j.yhbeh.2010.06.00710.1016/j.yhbeh.2010.06.007 ↗
10. 10.1016/j.psyneuen.2018.09.00310.1016/j.psyneuen.2018.09.003 ↗
11. 10.1038/s41380‐022‐01898‐910.1038/s41380‐022‐01898‐9 ↗
12. 10.1002/advs.20241595610.1002/advs.202415956 ↗
13. 10.1186/s13034‐024‐00847‐410.1186/s13034‐024‐00847‐4 ↗
14. 10.1038/s41421‐021‐00343‐510.1038/s41421‐021‐00343‐5 ↗
15. 10.1038/tp.2016.10910.1038/tp.2016.109 ↗
16. 10.1038/s41467‐020‐15305‐w10.1038/s41467‐020‐15305‐w ↗
17. 10.1080/15592294.2025.245717610.1080/15592294.2025.2457176 ↗
18. 10.1016/j.psyneuen.2023.10692310.1016/j.psyneuen.2023.106923 ↗
19. 10.3945/jn.110.13732310.3945/jn.110.137323 ↗
20. 10.1016/j.pbb.2006.03.00510.1016/j.pbb.2006.03.005 ↗
21. 10.1186/s12937‐022‐00783‐z10.1186/s12937‐022‐00783‐z ↗
22. 10.1016/j.tox.2019.15230210.1016/j.tox.2019.152302 ↗
23. 10.3945/ajcn.113.08007710.3945/ajcn.113.080077 ↗
24. 10.1016/j.fct.2022.11310210.1016/j.fct.2022.113102 ↗
25. 10.1002/advs.20240559210.1002/advs.202405592 ↗
26. 10.1016/j.psyneuen.2017.05.01410.1016/j.psyneuen.2017.05.014 ↗
27. 10.1186/s12915‐023‐01678‐z10.1186/s12915‐023‐01678‐z ↗
28. 10.1111/andr.1363610.1111/andr.13636 ↗
29. 10.1002/j.2040‐4603.2016.tb00694.x10.1002/j.2040‐4603.2016.tb00694.x ↗
30. 10.1080/10253890.2020.185947510.1080/10253890.2020.1859475 ↗
31. 10.1016/j.toxlet.2017.10.01910.1016/j.toxlet.2017.10.019 ↗
32. 10.1002/tox.2363010.1002/tox.23630 ↗
33. 10.1016/j.tox.2019.02.00810.1016/j.tox.2019.02.008 ↗
34. 10.1186/s40168‐023‐01656‐110.1186/s40168‐023‐01656‐1 ↗
35. 10.1038/s41585‐022‐00708‐910.1038/s41585‐022‐00708‐9 ↗
36. 10.1126/sciadv.abd760510.1126/sciadv.abd7605 ↗
37. 10.1016/j.fertnstert.2013.10.04210.1016/j.fertnstert.2013.10.042 ↗
38. 10.1111/acel.1304610.1111/acel.13046 ↗
39. 10.1016/j.neuropharm.2018.01.00910.1016/j.neuropharm.2018.01.009 ↗
40. 10.1002/embj.20138659110.1002/embj.201386591 ↗
41. 10.1093/nar/gkac34410.1093/nar/gkac344 ↗
42. 10.1016/B978-0-444-64123-6.00004-710.1016/B978-0-444-64123-6.00004-7 ↗
43. 10.1038/s41386‐018‐0167‐910.1038/s41386‐018‐0167‐9 ↗
44. 10.1146/annurev.clinpsy.4.022007.14124810.1146/annurev.clinpsy.4.022007.141248 ↗
45. 10.1038/mp.2016.12010.1038/mp.2016.120 ↗
46. 10.1038/s41386‐020‐00898‐z10.1038/s41386‐020‐00898‐z ↗
47. 10.1016/j.yfrne.2003.07.00110.1016/j.yfrne.2003.07.001 ↗
48. 10.1002/stem.43110.1002/stem.431 ↗
49. 10.1038/nsmb.157610.1038/nsmb.1576 ↗
50. 10.1038/s41398‐024‐03109‐110.1038/s41398‐024‐03109‐1 ↗
51. 10.1523/JNEUROSCI.3192‐20.202110.1523/JNEUROSCI.3192‐20.2021 ↗
52. 10.1038/s41398‐023‐02684‐z10.1038/s41398‐023‐02684‐z ↗
53. 10.1038/s41380‐023‐02350‐210.1038/s41380‐023‐02350‐2 ↗
54. 10.1080/15592294.2024.234669410.1080/15592294.2024.2346694 ↗
55. 10.1038/nn.369510.1038/nn.3695 ↗
56. 10.1073/pnas.150834711210.1073/pnas.1508347112 ↗
57. 10.1093/molehr/gax02910.1093/molehr/gax029 ↗
58. 10.1080/15592294.2024.238093010.1080/15592294.2024.2380930 ↗
59. 10.1016/B978-0-12-801022-8.00015-510.1016/B978-0-12-801022-8.00015-5 ↗
60. 10.3390/ijms25221200310.3390/ijms252212003 ↗
61. Longitudinal Effects of Lifetime Caffeine Consumption on Levels of Depression
62. 10.1016/j.ejogrb.2011.04.02410.1016/j.ejogrb.2011.04.024 ↗
63. 10.1016/j.fct.2017.04.00210.1016/j.fct.2017.04.002 ↗
64. 10.1093/milmed/usaf23310.1093/milmed/usaf233 ↗
65. 10.1016/j.yrtph.2017.07.02510.1016/j.yrtph.2017.07.025 ↗
66. 10.1016/bs.pbr.2024.06.01210.1016/bs.pbr.2024.06.012 ↗
67. 10.1016/j.smrv.2023.10176410.1016/j.smrv.2023.101764 ↗
68. 10.3390/nu1618315510.3390/nu16183155 ↗
69. 10.1038/nature1715610.1038/nature17156 ↗
70. 10.1016/j.neubiorev.2019.05.02310.1016/j.neubiorev.2019.05.023 ↗
71. 10.3988/jcn.2023.030810.3988/jcn.2023.0308 ↗
72. Realgar‐Induced CNS Toxicity: Exploring OTC‐Mediated Ornithine Regulation of ZBTB7A Inhibits Astrocyte Glycolysis Based on the Liver‐Brain Axis
73. 10.1016/j.expneurol.2020.11332910.1016/j.expneurol.2020.113329 ↗
74. 10.3389/fncel.2018.0039510.3389/fncel.2018.00395 ↗